
NATURE . COM {
}
Title:
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine
Description:
Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4–7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309 ). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21–41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Education
- Science
- Health & Fitness
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌆 Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,194,993 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$531,700 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $354,480 to $974,820.
Keywords {🔍}
article, cancer, nature, google, scholar, data, patients, cas, urothelial, neoadjuvant, oncology, research, analysis, response, carcinoma, hospital, clinical, study, access, bladder, biomarkers, baseline, tumor, med, medical, medicine, atezolizumab, trial, department, fundinghonoraria, content, metastatic, phase, cells, treatment, chemotherapy, clin, university, extended, samples, information, change, published, biomarker, powles, muscleinvasive, immunotherapy, advanced, nat, immune,
Topics {✒️}
nature portfolio journals permissions reprints nature portfolio privacy policy advertising muscle-invasive bladder cancer muscle-invasive urothelial cancer social media transforming growth factor-β protocol development open-label nature+ nature 554 nature pieter-jan van dam research funding/honoraria european genome-phenome archive alejo rodriguez-vida pd-1/pd-l1 blockade albert font pous cisplatin-based neoadjuvant chemotherapy accession number ega-box-1336 universidad de sevilla pd-1/pd-l1 immunotherapy high-risk resectable melanoma refractory solid tumors platinum-treated locally advanced permissions springerlink instant access barts cancer institute netherlands cancer institute santiago de compostela van der heijden extended data fig advanced urothelial cancers urbano anido herranz maria jose mendez neoadjuvant pd-1 blockade pd-l1 blockade data monitoring committee author correspondence fibroblast activation protein hospital del mar resting memory cells operable urothelial carcinoma gene expression signatures metastatic urothelial carcinoma resectable lung cancer privacy ligand 1 pd-l1
Schema {🗺️}
WebPage:
mainEntity:
headline:Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
description:Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4â7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier:
NCT02662309
). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21â41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
datePublished:2019-11-04T00:00:00Z
dateModified:2023-03-21T00:00:00Z
pageStart:1706
pageEnd:1714
sameAs:https://doi.org/10.1038/s41591-019-0628-7
keywords:
Bladder cancer
Predictive markers
Biomedicine
general
Cancer Research
Metabolic Diseases
Infectious Diseases
Molecular Medicine
Neurosciences
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig3_HTML.png
isPartOf:
name:Nature Medicine
issn:
1546-170X
1078-8956
volumeNumber:25
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Thomas Powles
url:http://orcid.org/0000-0001-7760-4724
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Mark Kockx
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Alejo Rodriguez-Vida
affiliation:
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Ignacio Duran
affiliation:
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
type:Organization
type:Person
name:Simon J. Crabb
url:http://orcid.org/0000-0003-3521-9064
affiliation:
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
type:Organization
type:Person
name:Michiel S. Van Der Heijden
affiliation:
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
type:Organization
type:Person
name:Bernadett Szabados
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Albert Font Pous
affiliation:
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
type:Organization
type:Person
name:Gwenaelle Gravis
affiliation:
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Urbano Anido Herranz
url:http://orcid.org/0000-0003-0376-5642
affiliation:
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
type:Organization
type:Person
name:Andrew Protheroe
url:http://orcid.org/0000-0001-9413-0575
affiliation:
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
type:Organization
type:Person
name:Alain Ravaud
affiliation:
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
type:Organization
type:Person
name:Denis Maillet
affiliation:
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
type:Organization
type:Person
name:Maria Jose Mendez
url:http://orcid.org/0000-0002-7460-1859
affiliation:
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
type:Organization
type:Person
name:Cristina Suarez
affiliation:
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Mark Linch
affiliation:
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
type:Organization
type:Person
name:Aaron Prendergast
url:http://orcid.org/0000-0002-9668-6689
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Pieter-Jan van Dam
url:http://orcid.org/0000-0001-9074-8271
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Diana Stanoeva
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sofie Daelemans
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sanjeev Mariathasan
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Joy S. Tea
url:http://orcid.org/0000-0002-3395-149X
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Kelly Mousa
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Romain Banchereau
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Daniel Castellano
affiliation:
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
description:Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4â7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier:
NCT02662309
). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21â41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
datePublished:2019-11-04T00:00:00Z
dateModified:2023-03-21T00:00:00Z
pageStart:1706
pageEnd:1714
sameAs:https://doi.org/10.1038/s41591-019-0628-7
keywords:
Bladder cancer
Predictive markers
Biomedicine
general
Cancer Research
Metabolic Diseases
Infectious Diseases
Molecular Medicine
Neurosciences
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig3_HTML.png
isPartOf:
name:Nature Medicine
issn:
1546-170X
1078-8956
volumeNumber:25
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Thomas Powles
url:http://orcid.org/0000-0001-7760-4724
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Mark Kockx
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Alejo Rodriguez-Vida
affiliation:
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Ignacio Duran
affiliation:
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
type:Organization
type:Person
name:Simon J. Crabb
url:http://orcid.org/0000-0003-3521-9064
affiliation:
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
type:Organization
type:Person
name:Michiel S. Van Der Heijden
affiliation:
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
type:Organization
type:Person
name:Bernadett Szabados
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Albert Font Pous
affiliation:
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
type:Organization
type:Person
name:Gwenaelle Gravis
affiliation:
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Urbano Anido Herranz
url:http://orcid.org/0000-0003-0376-5642
affiliation:
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
type:Organization
type:Person
name:Andrew Protheroe
url:http://orcid.org/0000-0001-9413-0575
affiliation:
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
type:Organization
type:Person
name:Alain Ravaud
affiliation:
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
type:Organization
type:Person
name:Denis Maillet
affiliation:
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
type:Organization
type:Person
name:Maria Jose Mendez
url:http://orcid.org/0000-0002-7460-1859
affiliation:
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
type:Organization
type:Person
name:Cristina Suarez
affiliation:
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
type:Organization
type:Person
name:Mark Linch
affiliation:
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
type:Organization
type:Person
name:Aaron Prendergast
url:http://orcid.org/0000-0002-9668-6689
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Pieter-Jan van Dam
url:http://orcid.org/0000-0001-9074-8271
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Diana Stanoeva
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sofie Daelemans
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
type:Organization
type:Person
name:Sanjeev Mariathasan
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Joy S. Tea
url:http://orcid.org/0000-0002-3395-149X
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Kelly Mousa
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
type:Person
name:Romain Banchereau
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
type:Person
name:Daniel Castellano
affiliation:
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Nature Medicine
issn:
1546-170X
1078-8956
volumeNumber:25
Organization:
name:Nature Publishing Group US
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Thomas Powles
url:http://orcid.org/0000-0001-7760-4724
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
email:[email protected]
name:Mark Kockx
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:Alejo Rodriguez-Vida
affiliation:
name:Hospital del Mar
address:
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
type:PostalAddress
type:Organization
name:Ignacio Duran
affiliation:
name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
address:
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
type:PostalAddress
type:Organization
name:Simon J. Crabb
url:http://orcid.org/0000-0003-3521-9064
affiliation:
name:University of Southampton
address:
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
type:PostalAddress
type:Organization
name:Michiel S. Van Der Heijden
affiliation:
name:The Netherlands Cancer Institute
address:
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
type:PostalAddress
type:Organization
name:Bernadett Szabados
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
name:Albert Font Pous
affiliation:
name:Hospital Universitari Germans Trias i Pujol
address:
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
type:PostalAddress
type:Organization
name:Gwenaelle Gravis
affiliation:
name:Institut Paoli-Calmettes
address:
name:Institut Paoli-Calmettes, Marseille, France
type:PostalAddress
type:Organization
name:Urbano Anido Herranz
url:http://orcid.org/0000-0003-0376-5642
affiliation:
name:Hospital Clinico Universitario de Santiago
address:
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
type:PostalAddress
type:Organization
name:Andrew Protheroe
url:http://orcid.org/0000-0001-9413-0575
affiliation:
name:Churchill Hospital
address:
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
type:PostalAddress
type:Organization
name:Alain Ravaud
affiliation:
name:University of BordeauxâCHU Bordeaux
address:
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
type:PostalAddress
type:Organization
name:Denis Maillet
affiliation:
name:Hospital Lyon Sud
address:
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
type:PostalAddress
type:Organization
name:Maria Jose Mendez
url:http://orcid.org/0000-0002-7460-1859
affiliation:
name:Reina Sofia University Hospital
address:
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
type:PostalAddress
type:Organization
name:Cristina Suarez
affiliation:
name:Vall dâHebron University Hospital, Universitat Autonoma de Barcelona
address:
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
type:PostalAddress
type:Organization
name:Mark Linch
affiliation:
name:University College London Hospital
address:
name:Department of Medical Oncology, University College London Hospital, London, UK
type:PostalAddress
type:Organization
name:Aaron Prendergast
url:http://orcid.org/0000-0002-9668-6689
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
name:Pieter-Jan van Dam
url:http://orcid.org/0000-0001-9074-8271
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:Diana Stanoeva
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:Sofie Daelemans
affiliation:
name:HistogeneX N.V.
address:
name:HistogeneX N.V., Wilrijk, Belgium
type:PostalAddress
type:Organization
name:University of Antwerp
address:
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
type:PostalAddress
type:Organization
name:Sanjeev Mariathasan
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
name:Joy S. Tea
url:http://orcid.org/0000-0002-3395-149X
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
name:Kelly Mousa
affiliation:
name:Queen Mary University of London
address:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
type:PostalAddress
type:Organization
name:Romain Banchereau
affiliation:
name:Genentech
address:
name:Genentech, San Francisco, USA
type:PostalAddress
type:Organization
name:Daniel Castellano
affiliation:
name:Hospital 12 de Octubre
address:
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
type:PostalAddress
type:Organization
PostalAddress:
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:HistogeneX N.V., Wilrijk, Belgium
name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
name:Institut Paoli-Calmettes, Marseille, France
name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
name:Department of Medical Oncology, Hopital Saint-Andre, University of BordeauxâCHU Bordeaux, Bordeaux, France
name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
name:Vall dâHebron Institute of Oncology, Vall dâHebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
name:Department of Medical Oncology, University College London Hospital, London, UK
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:HistogeneX N.V., Wilrijk, Belgium
name:HistogeneX N.V., Wilrijk, Belgium
name:HistogeneX N.V., Wilrijk, Belgium
name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
name:Genentech, San Francisco, USA
name:Genentech, San Francisco, USA
name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
name:Genentech, San Francisco, USA
name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
Social Networks {👍}(2)
External Links {🔗}(127)
- How much does https://orcid.org/0000-0001-7760-4724 bring in each month?
- How much does https://orcid.org/0000-0003-3521-9064 bring in each month?
- What's the financial intake of https://orcid.org/0000-0003-0376-5642?
- Earnings of https://orcid.org/0000-0001-9413-0575
- What's the profit of https://orcid.org/0000-0002-7460-1859?
- What is the earnings of https://orcid.org/0000-0002-9668-6689?
- What's the revenue for https://orcid.org/0000-0001-9074-8271?
- How much does https://orcid.org/0000-0002-3395-149X earn?
- How much money does https://doi.org/10.1038/s41591-023-02312-9 generate?
- How much income does https://doi.org/10.1038/s41591-020-0923-3 have?
- Find out how much https://clinicaltrials.gov/ct2/show/NCT02662309?term=NCT02662309&rank=1 earns monthly
- What's the financial outcome of https://link.springer.com/article/10.1038/s41591-019-0628-7?utm_source=nature&utm_medium=referral&utm_campaign=buyArticle?
- How much revenue does https://doi.org/10.1016%2Fj.ctrv.2017.01.007 produce monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=A%20review%20on%20the%20evolution%20of%20PD-1%2FPD-L1%20immunotherapy%20for%20bladder%20cancer%3A%20the%20future%20is%20now&journal=Cancer%20Treat.%20Rev.&doi=10.1016%2Fj.ctrv.2017.01.007&volume=54&pages=58-67&publication_year=2017&author=Bellmunt%2CJ&author=Powles%2CT&author=Vogelzang%2CNJ earn?
- Monthly income for https://doi.org/10.1016%2FS0140-6736%2817%2933297-X
- http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20versus%20chemotherapy%20in%20patients%20with%20platinum-treated%20locally%20advanced%20or%20metastatic%20urothelial%20carcinoma%20%28IMvigor211%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%203%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2817%2933297-X&volume=391&pages=748-757&publication_year=2018&author=Powles%2CT's revenue stream
- Income figures for https://doi.org/10.1038%2Fnature25501
- How much does http://scholar.google.com/scholar_lookup?&title=TGF-%CE%B2%20attenuates%20tumour%20response%20to%20PD-L1%20blockade%20by%20contributing%20to%20exclusion%20of%20T%20cells&journal=Nature&doi=10.1038%2Fnature25501&volume=554&pages=544-548&publication_year=2018&author=Mariathasan%2CS earn?
- How much profit does https://doi.org/10.1038%2Fs41591-018-0198-0 generate?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20versus%20adjuvant%20ipilimumab%20plus%20nivolumab%20in%20macroscopic%20stage%20III%20melanoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0198-0&volume=24&pages=1655-1661&publication_year=2018&author=Blank%2CCU?
- Revenue of https://doi.org/10.1200%2FJCO.18.01148
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20as%20neoadjuvant%20therapy%20before%20radical%20cystectomy%20in%20patients%20with%20muscle-invasive%20urothelial%20bladder%20carcinoma%20%28PURE-01%29%3A%20an%20open-label%2C%20single-arm%2C%20phase%20II%20study&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.18.01148&volume=36&pages=3353-3360&publication_year=2018&author=Necchi%2CA each month?
- How much profit is https://doi.org/10.1038%2Fs41591-018-0337-7 making per month?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20anti-PD-1%20immunotherapy%20promotes%20a%20survival%20benefit%20with%20intratumoral%20and%20systemic%20immune%20responses%20in%20recurrent%20glioblastoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0337-7&volume=25&pages=477-486&publication_year=2019&author=Cloughesy%2CTF
- What's the income generated by https://doi.org/10.1038%2Fs41591-018-0197-1 each month?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20immune%20checkpoint%20blockade%20in%20high-risk%20resectable%20melanoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0197-1&volume=24&pages=1649-1654&publication_year=2018&author=Amaria%2CRN bring in?
- How much does https://doi.org/10.1016%2Fj.eururo.2014.01.009 earn?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Trends%20in%20the%20use%20of%20perioperative%20chemotherapy%20for%20localized%20and%20locally%20advanced%20muscle-invasive%20bladder%20cancer%3A%20a%20sign%20of%20changing%20tides&journal=Eur.%20Urol.&doi=10.1016%2Fj.eururo.2014.01.009&volume=67&pages=165-170&publication_year=2015&author=Reardon%2CZD earns monthly
- Financial intake of https://doi.org/10.1200%2FJCO.2010.32.3139
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=International%20phase%20III%20trial%20assessing%20neoadjuvant%20cisplatin%2C%20methotrexate%2C%20and%20vinblastine%20chemotherapy%20for%20muscle-invasive%20bladder%20cancer%3A%20long-term%20results%20of%20the%20BA06%2030894%20trial&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2010.32.3139&volume=29&pages=2171-2177&publication_year=2011?
- Earnings of https://doi.org/10.1158%2F1078-0432.CCR-15-1208
- How much profit does http://scholar.google.com/scholar_lookup?&title=Pathological%20T0%20following%20cisplatin-based%20neoadjuvant%20chemotherapy%20for%20muscle-invasive%20bladder%20cancer%3A%20a%20network%20meta-analysis&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-15-1208&volume=22&pages=1086-1094&publication_year=2016&author=Kim%2CHS&author=Jeong%2CCW&author=Kwak%2CC&author=Kim%2CHH&author=Ku%2CJH generate?
- https://doi.org/10.1056%2FNEJMoa1716078 income
- Revenue of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20blockade%20in%20resectable%20lung%20cancer&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1716078&volume=378&pages=1976-1986&publication_year=2018&author=Forde%2CPM
- What's the monthly income of https://doi.org/10.1038%2Fs41591-019-0357-y?
- Income figures for http://scholar.google.com/scholar_lookup?&title=A%20single%20dose%20of%20neoadjuvant%20PD-1%20blockade%20predicts%20clinical%20outcomes%20in%20resectable%20melanoma&journal=Nat.%20Med.&doi=10.1038%2Fs41591-019-0357-y&volume=25&pages=454-461&publication_year=2019&author=Huang%2CAC
- What's the profit of https://doi.org/10.1016%2FS0140-6736%2816%2900561-4?
- How much income is http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy%3A%20a%20single-arm%2C%20multicentre%2C%20phase%202%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2900561-4&volume=387&pages=1909-1920&publication_year=2016&author=Rosenberg%2CJE earning monthly?
- How much money does https://doi.org/10.1016%2Fj.cellimm.2007.07.004 generate?
- How much money does http://scholar.google.com/scholar_lookup?&title=Granzyme%20B%20production%20distinguishes%20recently%20activated%20CD8%2B%20memory%20cells%20from%20resting%20memory%20cells&journal=Cell%20Immunol&doi=10.1016%2Fj.cellimm.2007.07.004&volume=247&pages=36-48&publication_year=2007&author=Nowacki%2CTM make?
- Income figures for https://doi.org/10.1200%2FJCO.2018.36.6_suppl.409
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20%28atezo%29%20vs.%20chemotherapy%20%28chemo%29%20in%20platinum-treated%20locally%20advanced%20or%20metastatic%20urothelial%20carcinoma%20%28mUC%29%3A%20immune%20biomarkers%2C%20tumor%20mutational%20burden%20%28TMB%29%2C%20and%20clinical%20outcomes%20from%20the%20phase%20III%20IMvigor211%20study&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2018.36.6_suppl.409&volume=36&pages=409-409&publication_year=2018&author=Powles%2CT?
- How much profit does https://doi.org/10.1200%2FJCO.2017.75.7740 generate?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Alterations%20in%20DNA%20damage%20response%20and%20repair%20genes%20as%20potential%20marker%20of%20clinical%20benefit%20from%20PD-1%2FPD-L1%20blockade%20in%20advanced%20urothelial%20cancers&journal=J.%20Clin.%20Oncol.&doi=10.1200%2FJCO.2017.75.7740&volume=36&pages=1685-1694&publication_year=2018&author=Teo%2CMY each month?
- How much revenue does https://doi.org/10.1038%2Fnm.2807 generate?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20fibrosis%3A%20therapeutic%20translation%20for%20fibrotic%20disease&journal=Nat.%20Med.&doi=10.1038%2Fnm.2807&volume=18&pages=1028-1040&publication_year=2012&author=Wynn%2CTA&author=Ramalingam%2CTR earns monthly
- How much does https://doi.org/10.1038%2Fonc.2016.353 make?
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Cancer-associated%20fibroblast%20exosomes%20regulate%20survival%20and%20proliferation%20of%20pancreatic%20cancer%20cells&journal=Oncogene&doi=10.1038%2Fonc.2016.353&volume=36&pages=1770-1778&publication_year=2017&author=Richards%2CKE?
- Monthly income for https://doi.org/10.1158%2F1078-0432.CCR-12-0077-T
- Financial intake of http://scholar.google.com/scholar_lookup?&title=A%20molecular%20taxonomy%20for%20urothelial%20carcinoma&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-12-0077-T&volume=18&pages=3377-3386&publication_year=2012&author=Sjodahl%2CG
- Find out how much https://doi.org/10.1016%2Fj.eururo.2018.09.003 earns monthly
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Intratumoral%20heterogeneity%20of%20bladder%20cancer%20by%20molecular%20subtypes%20and%20histologic%20variants&journal=Eur.%20Urol.&doi=10.1016%2Fj.eururo.2018.09.003&volume=75&pages=18-22&publication_year=2019&author=Warrick%2CJI?
- What's the profit of https://doi.org/10.1080%2F2162402X.2018.1488359?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=WEE1%20kinase%20inhibition%20reverses%20G2%2FM%20cell%20cycle%20checkpoint%20activation%20to%20sensitize%20cancer%20cells%20to%20immunotherapy&journal=Oncoimmunology&doi=10.1080%2F2162402X.2018.1488359&volume=7&publication_year=2018&author=Sun%2CL generate?
- How much money does https://doi.org/10.1158%2F1078-0432.CCR-18-3334 generate?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20I%20study%20of%20erdafitinib%20%28JNJ-42756493%29%2C%20oral%20pan-fibroblast%20growth%20factor%20receptor%20inhibitor%2C%20in%20patients%20with%20advanced%20or%20refractory%20solid%20tumors&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-18-3334&volume=25&pages=4888-4897&publication_year=2019&author=Bahleda%2CR?
- Income figures for https://doi.org/10.1158%2F1078-0432.CCR-18-3147
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Mutational%20analysis%20of%20472%20urothelial%20carcinoma%20across%20grades%20and%20anatomic%20sites&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-18-3147&volume=25&pages=2458-2470&publication_year=2019&author=Nassar%2CAH
- What's the financial intake of https://doi.org/10.1056%2FNEJMoa1817323?
- Get to know http://scholar.google.com/scholar_lookup?&title=Erdafitinib%20in%20locally%20advanced%20or%20metastatic%20urothelial%20carcinoma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1817323&volume=381&pages=338-348&publication_year=2019&author=Loriot%2CY's earnings
- How much revenue does https://doi.org/10.1002%2Fsim.721 produce monthly?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Sample%20size%20tables%20for%20exact%20single-stage%20phase%20II%20designs&journal=Stat.%20Med.&doi=10.1002%2Fsim.721&volume=20&pages=859-866&publication_year=2001&author=A%E2%80%99Hern%2CRP?
- Income figures for https://citation-needed.springer.com/v2/references/10.1038/s41591-019-0628-7?format=refman&flavour=references
- What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20Powles?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20Powles%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
- What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20Kockx?
- Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20Kockx%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alejo%20Rodriguez-Vida?
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alejo%20Rodriguez-Vida%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ignacio%20Duran pull in monthly?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ignacio%20Duran%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
- Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Simon%20J.%20Crabb
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Simon%20J.%20Crabb%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michiel%20S.%20Van%20Der%20Heijden?
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michiel%20S.%20Van%20Der%20Heijden%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bernadett%20Szabados have monthly?
- Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bernadett%20Szabados%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Albert%20Font%20Pous generate?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Albert%20Font%20Pous%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gwenaelle%20Gravis pull in?
- Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gwenaelle%20Gravis%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Urbano%20Anido%20Herranz making per month?
- What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Urbano%20Anido%20Herranz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Andrew%20Protheroe rake in every month?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Andrew%20Protheroe%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alain%20Ravaud?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alain%20Ravaud%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Denis%20Maillet each month?
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Denis%20Maillet%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Maria%20Jose%20Mendez?
- What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Maria%20Jose%20Mendez%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Learn how profitable https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cristina%20Suarez is on a monthly basis
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cristina%20Suarez%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mark%20Linch making per month?
- What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mark%20Linch%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the revenue for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Aaron%20Prendergast?
- What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Aaron%20Prendergast%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Pieter-Jan%20van%20Dam?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Pieter-Jan%20van%20Dam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Diana%20Stanoeva income
- What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Diana%20Stanoeva%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sofie%20Daelemans
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sofie%20Daelemans%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sanjeev%20Mariathasan generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sanjeev%20Mariathasan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
- What's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Joy%20S.%20Tea?
- How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Joy%20S.%20Tea%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
- Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kelly%20Mousa
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kelly%20Mousa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Romain%20Banchereau's financial summary
- What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Romain%20Banchereau%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
- Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daniel%20Castellano
- Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daniel%20Castellano%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What's the financial intake of https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_MOESM1_ESM.pdf?
- Check the income stats for https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_MOESM2_ESM.pdf
- Explore the financials of https://s100.copyright.com/AppDispatchServlet?title=Clinical%20efficacy%20and%20biomarker%20analysis%20of%20neoadjuvant%20atezolizumab%20in%20operable%20urothelial%20carcinoma%20in%20the%20ABACUS%20trial&author=Thomas%20Powles%20et%20al&contentID=10.1038%2Fs41591-019-0628-7©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20America%2C%20Inc.&publication=1078-8956&publicationDate=2019-11-04&publisherName=SpringerNature&orderBeanReset=true
- Learn about the earnings of https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-019-0628-7
- How much does https://citation-needed.springer.com/v2/references/10.1038/s41591-019-0628-7?format=refman&flavour=citation pull in?
- What is the monthly revenue of https://doi.org/10.1038/s41698-025-00846-4?
- What's the profit of https://doi.org/10.1038/s41571-024-00984-x?
- Check the income stats for https://doi.org/10.1038/s43018-025-00990-7
- How much does https://doi.org/10.1038/s41467-024-55665-1 pull in?
- How much profit does https://doi.org/10.1038/s41598-025-99889-7 generate?
- Financial intake of https://www.protocols.io/
- Revenue of https://www.natureindex.com/
- http://www.naturechina.com income
- What's https://www.natureasia.com/ja-jp's gross income?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref